Ignite Creation Date:
2024-07-17 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06480565
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-28
First Post:
2024-06-25
Brief Title:
A Phase 12 Trial of ADI-270 in ccRCC
Sponsor:
Adicet Therapeutics
Organization:
Adicet Therapeutics
Study Overview
Official Title:
A Phase 12 Trial of ADI-270 Engineered γδ Chimeric Receptor CAR Vδ1 T Cells Targeting CD70 in Adults With Relapsed or Refractory RR Clear Cell Renal Cell Carcinoma ccRCC
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 12 multicenter open-label dose escalation and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor CAR Vδ1 T Cell product Targeting CD70 - in patients with RR ccRCC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None